Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Change in Acquisitions & Divestments (2020 - 2022)

Historic Change in Acquisitions & Divestments for Apellis Pharmaceuticals (APLS) over the last 3 years, with Q4 2022 value amounting to $125.0 million.

  • Apellis Pharmaceuticals' Change in Acquisitions & Divestments rose 4703.53% to $125.0 million in Q4 2022 from the same period last year, while for Dec 2022 it was $393.3 million, marking a year-over-year decrease of 636.19%. This contributed to the annual value of $393.3 million for FY2022, which is 636.19% down from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Change in Acquisitions & Divestments stood at $125.0 million for Q4 2022, which was up 4703.53% from $125.0 million recorded in Q3 2022.
  • Apellis Pharmaceuticals' Change in Acquisitions & Divestments' 5-year high stood at $312.5 million during Q4 2020, with a 5-year trough of $25.0 million in Q1 2021.
  • Over the past 3 years, Apellis Pharmaceuticals' median Change in Acquisitions & Divestments value was $125.0 million (recorded in 2022), while the average stood at $132.8 million.
  • Per our database at Business Quant, Apellis Pharmaceuticals' Change in Acquisitions & Divestments plummeted by 7280.0% in 2021 and then surged by 14000.0% in 2022.
  • Apellis Pharmaceuticals' Change in Acquisitions & Divestments (Quarter) stood at $312.5 million in 2020, then crashed by 72.8% to $85.0 million in 2021, then skyrocketed by 47.04% to $125.0 million in 2022.
  • Its Change in Acquisitions & Divestments stands at $125.0 million for Q4 2022, versus $125.0 million for Q3 2022 and $83.3 million for Q2 2022.